Panel Discussion | Our Understanding of the Pathophysiology and Mechanism of Atherosclerosis and the New Therapeutic Options

Sunday, March 8, 2026

2:26 PM - 2:45 PM EST

Location: Monroe

Moderator(s)

Takashi Akasaka, MD, PhD

Senior Consultant
Nishinomiya Watanabe Cardiovascular Cerebral Center
Nishinomiya, Hyogo, Japan

Disclosure(s): Abbott Medical: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, December 18, 2025)
Rasha Al-Lamee, MA, MD, PhD

Interventional Cardiology Consultant
Imperial College London
London, England, United Kingdom

Disclosure(s): Abbott Vascular,: Consulting Fees (e.g., advisory boards) (Ongoing); AstraZeneca Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing); CathWorks: Consulting Fees (e.g., advisory boards) (Ongoing); Jannsen: Consulting Fees (e.g., advisory boards) (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Philips Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Shockwave Medical: Consulting Fees (e.g., advisory boards) (Ongoing)
Renu Virmani, MD

President
CVPath Institute, Inc.
Gaithersburg, Maryland, United States

Disclosure(s): No financial relationships to disclose

Panel Discussant(s)

Usman Baber, MD, MS

Professor of Medicine
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States

Disclosure(s): AstraZeneca Pharmaceuticals: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boston Scietific: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
Charles German, MD, MS, FAHA, FASPC

Assistant Professor
Georgetown University

Disclosure(s): No financial relationships to disclose
Ramzi Khamis, MB, ChB, PhD, FRCP, FESC

Professor of Cardiology. Consultant Cardiologist.
Imperial College London and Imperial College Healthcare NHS Trust
London, England, United Kingdom

Disclosure(s): No financial relationships to disclose
Seth S. Martin, MD, MHS, FACC, FAHA, FASPC

Professor
Johns Hopkins
Reisterstown, Maryland, United States

Disclosure(s): Amgen, Arrowhead, Chroma, HeartFlow, Kaneka, Merck, NewAmsterdam, Novartis, Pfizer, Sanofi, and Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Corrie Health: Owner/Co-Owner Founder/Co-Founder (Ongoing), Stock-privately held company (Ongoing)
Paul M. Ridker, MD

Director, Center for Cardiovascular Disease Prevention
Brigham and Womens Hospital
Brookline, Massachusetts, United States

Disclosure(s): Kowa, Novartis, Amarin, Pfizer, Esperion, NovoNordisk, NHLBI, NCI: Grant/Research Support (Ongoing); Novartis, Agepha, Ardelyx, Arrowhead, AstraZeneca, CSL Behring, Janssen, Vivi Biopharm, Glaso Smith Kline, SOCAR, Novo Nordisk, Eli Lilly, new Amsterdam, Boehringer-Ingelheim, Cytokinetics, Nodthera, Tourmaline Bio, Cardio therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Uppton, Bitteroot, Bio, Angiowave and receives compensation for service from Leducq Foundation, Paris FR: Minority shareholder equity positions (Ongoing)
Robert S. Rosenson, MD

Director of Metabolism and Lipids
Mount Sinai Health System
New York, New York, United States

Disclosure(s): 89Bio: Grant/Research Support (Ongoing); Amgen Inc: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Arrowhead Pharmaceuticals, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); AstraZeneca Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); CRISPR Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Eli Lilly and Company: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Kowa Pharmaceuticals: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Lipigon Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Merck Pharmaceuticals: Grant/Research Support (Ongoing); NIH: Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Precision BioSciences: Consulting Fees (e.g., advisory boards) (Ongoing); Regeneron Pharma: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Ultragenyx Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Wolters Kluwer Pharma: Royalties (Ongoing)
Allen J. Taylor, MD

Chairman of Cardiology
MedStar Heart and Vascular Institute
Washington, District of Columbia, United States

Disclosure(s): Heartflow Inc.: Consulting Fees (e.g., advisory boards) (Ongoing)

Disclosure(s):

Takashi Akasaka, MD, PhD: Abbott Medical: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, December 18, 2025)

Rasha Al-Lamee, MA, MD, PhD: Abbott Vascular,: Consulting Fees (e.g., advisory boards) (Ongoing); AstraZeneca Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing); CathWorks: Consulting Fees (e.g., advisory boards) (Ongoing); Jannsen: Consulting Fees (e.g., advisory boards) (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Philips Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Shockwave Medical: Consulting Fees (e.g., advisory boards) (Ongoing)

Renu Virmani, MD: No financial relationships to disclose

Usman Baber, MD, MS: AstraZeneca Pharmaceuticals: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boston Scietific: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Charles German, MD, MS, FAHA, FASPC: No financial relationships to disclose

Ramzi Khamis, MB, ChB, PhD, FRCP, FESC: No financial relationships to disclose

Seth S. Martin, MD, MHS, FACC, FAHA, FASPC: Amgen, Arrowhead, Chroma, HeartFlow, Kaneka, Merck, NewAmsterdam, Novartis, Pfizer, Sanofi, and Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Corrie Health: Owner/Co-Owner Founder/Co-Founder (Ongoing), Stock-privately held company (Ongoing)

Paul M. Ridker, MD: Kowa, Novartis, Amarin, Pfizer, Esperion, NovoNordisk, NHLBI, NCI: Grant/Research Support (Ongoing); Novartis, Agepha, Ardelyx, Arrowhead, AstraZeneca, CSL Behring, Janssen, Vivi Biopharm, Glaso Smith Kline, SOCAR, Novo Nordisk, Eli Lilly, new Amsterdam, Boehringer-Ingelheim, Cytokinetics, Nodthera, Tourmaline Bio, Cardio therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Uppton, Bitteroot, Bio, Angiowave and receives compensation for service from Leducq Foundation, Paris FR: Minority shareholder equity positions (Ongoing)

Robert S. Rosenson, MD: 89Bio: Grant/Research Support (Ongoing); Amgen Inc: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Arrowhead Pharmaceuticals, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); AstraZeneca Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); CRISPR Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Eli Lilly and Company: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Kowa Pharmaceuticals: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Lipigon Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Merck Pharmaceuticals: Grant/Research Support (Ongoing); NIH: Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Precision BioSciences: Consulting Fees (e.g., advisory boards) (Ongoing); Regeneron Pharma: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Ultragenyx Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Wolters Kluwer Pharma: Royalties (Ongoing)

Allen J. Taylor, MD: Heartflow Inc.: Consulting Fees (e.g., advisory boards) (Ongoing)